BRAF L525R

CI-VAR-00002356Explore in graph →NP_001341538.1:p.Leu525ArgNM_001354609.2:c.1574T>GClinVar 372626 CIViC 2793 rs869025340

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Solid Neoplasm1
BRAF L525R	Cetuximab	Predictive	D	Supports Resistance	3	accepted	EID7560 When transferred into EGFR expressing HEK293 cells, BRAF L525R induced increased ERK phosphorylation to a level similar to that induced by BRAF V600E. ERK phosphorylation enhanced by BRAF L525R was no… (full text at CIViC) PMID 28972961 · Shinozaki et al., 2017 · Open in CIViC	civic
Unmapped disease2unmapped disease
BRAF L525R	(functional)	Functional	D	Supports Gain Of Function	3	accepted	EID7559 When transferred into EGFR expressing HEK293 cells, BRAF L525R induced increased ERK phosphorylation to a level similar to that induced by BRAF V600E. PMID 28972961 · Shinozaki et al., 2017 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
372626	Pathogenic	criteria provided, single submitter	1	Malignant lymphoma, large B-cell, diffuse	germline/somatic	2	May 29, 2024	clinvar